These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36485104)

  • 21. Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.
    Doorduijn JK; Zijlstra JM; Lugtenburg PJ; Kersten MJ; Böhmer LH; Minnema MC; MacKenzie MA; van Marwijk Kooij R; de Jongh E; Snijders TJF; de Weerdt O; van Gelder M; Hoogendoorn M; Leys RBL; Kibbelaar RE; de Jong D; Chitu DA; Van't Veer MB; Kluin-Nelemans HC
    Br J Haematol; 2020 Aug; 190(3):385-393. PubMed ID: 32150297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis.
    Mangel J; Leitch HA; Connors JM; Buckstein R; Imrie K; Spaner D; Crump M; Pennell N; Boudreau A; Berinstein NL
    Ann Oncol; 2004 Feb; 15(2):283-90. PubMed ID: 14760123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.
    Budde LE; Guthrie KA; Till BG; Press OW; Chauncey TR; Pagel JM; Petersdorf SH; Bensinger WI; Holmberg LA; Shustov AR; Green DJ; Maloney DG; Gopal AK
    J Clin Oncol; 2011 Aug; 29(22):3023-9. PubMed ID: 21730271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward?
    Mondello P; Steiner N; Willenbacher W; Arrigo C; Cuzzocrea S; Pitini V; Mian M
    Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):82-8. PubMed ID: 26702476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients.
    Dreger P; Martin S; Kuse R; Sonnen R; Glass B; Kröger N; Parwaresch R; Kneba M; Schmitz N; Haas R
    Hematol J; 2000; 1(2):87-94. PubMed ID: 11920175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma.
    Ng ZY; Bishton M; Ritchie D; Campbell R; Gilbertson M; Hill K; Ratnasingam S; Schwarer A; Manos K; Shorten S; Ng M; Nelson N; Xin L; De Mel Widanalage S; Sunny T; Purtill D; Poon M; Johnston A; Cochrane T; Lee HP; Hapgood G; Tam C; Opat S; Hawkes E; Seymour J; Cheah CY
    Hematol Oncol; 2019 Aug; 37(3):253-260. PubMed ID: 30983008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome of patients with mantle cell lymphoma after autologous stem cell transplantation in the pre-CAR T-cell era.
    Mathys A; Bacher U; Banz Y; Legros M; Mansouri Taleghani B; Novak U; Pabst T
    Hematol Oncol; 2022 Apr; 40(2):292-296. PubMed ID: 34817087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
    Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
    Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma.
    Villa D; Hoster E; Hermine O; Klapper W; Szymczyk M; Bosly A; Unterhalt M; Rimsza LM; Ramsower CA; Freeman CL; Scott DW; Gerrie AS; Savage KJ; Sehn LH; Dreyling M
    Blood Adv; 2022 Sep; 6(18):5285-5294. PubMed ID: 35439293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome.
    Dreger P; Rieger M; Seyfarth B; Hensel M; Kneba M; Ho AD; Schmitz N; Pott C
    Haematologica; 2007 Jan; 92(1):42-9. PubMed ID: 17229634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.
    Damon LE; Johnson JL; Niedzwiecki D; Cheson BD; Hurd DD; Bartlett NL; Lacasce AS; Blum KA; Byrd JC; Kelly M; Stock W; Linker CA; Canellos GP
    J Clin Oncol; 2009 Dec; 27(36):6101-8. PubMed ID: 19917845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Controversies in the treatment of lymphoma with autologous transplantation.
    Moskowitz AJ; Moskowitz CH
    Oncologist; 2009 Sep; 14(9):921-9. PubMed ID: 19737999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autologous hematopoietic cell transplantation of mantle cell lymphoma: emerging trends.
    Falcone U; Kuruvilla J
    Curr Opin Hematol; 2017 Nov; 24(6):502-508. PubMed ID: 28832354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma.
    Till BG; Gooley TA; Crawford N; Gopal AK; Maloney DG; Petersdorf SH; Pagel JM; Holmberg L; Bensinger W; Press OW
    Leuk Lymphoma; 2008 Jun; 49(6):1062-73. PubMed ID: 18452065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.
    Gerson JN; Handorf E; Villa D; Gerrie AS; Chapani P; Li S; Medeiros LJ; Wang MI; Cohen JB; Calzada O; Churnetski MC; Hill BT; Sawalha Y; Hernandez-Ilizaliturri FJ; Kothari S; Vose JM; Bast MA; Fenske TS; Narayana Rao Gari S; Maddocks KJ; Bond D; Bachanova V; Kolla B; Chavez J; Shah B; Lansigan F; Burns TF; Donovan AM; Wagner-Johnston N; Messmer M; Mehta A; Anderson JK; Reddy N; Kovach AE; Landsburg DJ; Glenn M; Inwards DJ; Karmali R; Kaplan JB; Caimi PF; Rajguru S; Evens A; Klein A; Umyarova E; Pulluri B; Amengual JE; Lue JK; Diefenbach C; Fisher RI; Barta SK
    J Clin Oncol; 2019 Feb; 37(6):471-480. PubMed ID: 30615550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission.
    Chakhachiro ZI; Saliba RM; Okoroji GJ; Korbling M; Alousi AM; Betul O; Anderlini P; Ciurea SO; Popat U; Champlin R; Samuels BI; Medeiros LJ; Bueso-Ramos C; Khouri IF
    Cancer; 2013 Sep; 119(18):3318-25. PubMed ID: 23775587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.
    Greenwell IB; Staton AD; Lee MJ; Switchenko JM; Saxe DF; Maly JJ; Blum KA; Grover NS; Mathews SP; Gordon MJ; Danilov AV; Epperla N; Fenske TS; Hamadani M; Park SI; Flowers CR; Cohen JB
    Cancer; 2018 Jun; 124(11):2306-2315. PubMed ID: 29579328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.
    Chen RW; Li H; Bernstein SH; Kahwash S; Rimsza LM; Forman SJ; Constine L; Shea TC; Cashen AF; Blum KA; Fenske TS; Barr PM; Phillips T; Leblanc M; Fisher RI; Cheson BD; Smith SM; Faham M; Wilkins J; Leonard JP; Kahl BS; Friedberg JW
    Br J Haematol; 2017 Mar; 176(5):759-769. PubMed ID: 27992063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).
    Chang JE; Li H; Smith MR; Gascoyne RD; Paietta EM; Yang DT; Advani RH; Horning SJ; Kahl BS
    Blood; 2014 Mar; 123(11):1665-73. PubMed ID: 24458437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.
    Zoellner AK; Unterhalt M; Stilgenbauer S; Hübel K; Thieblemont C; Metzner B; Topp M; Truemper L; Schmidt C; Bouabdallah K; Krauter J; Lenz G; Dürig J; Vergote V; Schäfer-Eckart K; André M; Kluin-Nelemans HC; van Hoof A; Klapper W; Hiddemann W; Dreyling M; Hoster E;
    Lancet Haematol; 2021 Sep; 8(9):e648-e657. PubMed ID: 34450102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.